Showing 1521-1530 of 4118 results for "".
Can Prescription Hyperhidrosis Treatments Help Mitigate Symptoms?
https://practicaldermatology.com/topics/rare-disease/can-prescription-hyperhidrosis-treatments-help-mitigate-symptoms/39997/DermWireTV: Ped Derm Salaries; Skin Cancer Symposium Kicks Off; Pandemic Self Care Stats
https://practicaldermatology.com/topics/practice-management/dermwiretv-ped-derm-salaries-skin-cancer-symposium-kicks-off-pandemic-self-care-stats/19910/According to the Society for Pediatric Dermatology’s 2020 Pediatric Dermatology Physician Compensation Report, salaries have increased 37% since 2014. Pediatric dermatologist Mercedes Gonzalez, MD comments. The inaugural Skin Cancer Symposium is underway and the Symposium for Inflammatory Disease kiUpdate on Pediatric Psoriasis
https://practicaldermatology.com/columns/clinical-focus-1/update-on-pediatric-psoriasis/23358/New guidelines and new treatments seek to dramatically improve lives of children with psoriasis.The Impact of Socioeconomic Status in Atopic Dermatitis and How the Internet Can Act as a Public Health Intervention
https://practicaldermatology.com/youngmd-connect/resident-resource-center/the-impact-of-socioeconomic-status-in-atopic-dermatitis-and-how-the-internet-can-act-as-a-public-health-intervention/23326/CBD in the Holistic Practice of Dermatology
https://practicaldermatology.com/topics/psoriasis/cbd-in-the-holistic-practice-of-dermatology/23319/A growing body evidence suggests CBD may help with common symptoms of dermatologic diseases. Here’s what we know so far.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://practicaldermatology.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended survivMoisturizers for Skin Diseases: New Insights
https://practicaldermatology.com/topics/atopic-dermatitis/moisturizers-for-skin-diseases-new-insights/22977/Exploring Patient-Reported Outcomes Measures in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/exploring-patient-reported-outcomes-measures-in-atopic-dermatitis/23886/Patient-reported outcomes may solve some of the challenges with measuring the physical and psychosocial manifestations.Drug-Induced Dermatomyositis
https://practicaldermatology.com/topics/atopic-dermatitis/drug-induced-dermatomyositis/23357/It’s common practice to screen for underlying malignancy in dermatomyositis, but it is also important to look for drug-induced disease.